| Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America PG Pappas, CA Kauffman, DR Andes, CJ Clancy, KA Marr, ... Clinical infectious diseases 62 (4), e1-e50, 2016 | 4248 | 2016 |
| Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group … JP Donnelly, SC Chen, CA Kauffman, WJ Steinbach, JW Baddley, ... Clinical Infectious Diseases 71 (6), 1367-1376, 2020 | 2123 | 2020 |
| Candida and candidiasis RA Calderone, CJ Clancy American Society for Microbiology Press, 2011 | 1129 | 2011 |
| Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care CJ Clancy, MH Nguyen Clinical infectious diseases 56 (9), 1284-1292, 2013 | 730 | 2013 |
| Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales … PD Tamma, SL Aitken, RA Bonomo, AJ Mathers, D Van Duin, CJ Clancy Clinical Infectious Diseases 72 (7), e169-e183, 2021 | 551 | 2021 |
| Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae … RK Shields, L Chen, S Cheng, KD Chavda, EG Press, A Snyder, ... Antimicrobial agents and chemotherapy 61 (3), 10.1128/aac. 02097-16, 2017 | 502 | 2017 |
| Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia RK Shields, MH Nguyen, L Chen, EG Press, BA Potoski, RV Marini, Y Doi, ... Antimicrobial agents and chemotherapy 61 (8), 10.1128/aac. 00883-17, 2017 | 491 | 2017 |
| T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial E Mylonakis, CJ Clancy, L Ostrosky-Zeichner, KW Garey, GJ Alangaden, ... Clinical Infectious Diseases 60 (6), 892-899, 2015 | 459 | 2015 |
| Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections RK Shields, BA Potoski, G Haidar, B Hao, Y Doi, L Chen, EG Press, ... Clinical Infectious Diseases 63 (12), 1615-1618, 2016 | 453 | 2016 |
| Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and … PD Tamma, SL Aitken, RA Bonomo, AJ Mathers, D Van Duin, CJ Clancy Clinical infectious diseases 74 (12), 2089-2114, 2022 | 444 | 2022 |
| Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America PG Pappas, CA Kauffman, DR Andes, CJ Clancy, KA Marr, ... Clinical Infectious Diseases 62 (4), 409-417, 2016 | 380 | 2016 |
| Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion PE Verweij, BJA Rijnders, RJM Brüggemann, E Azoulay, M Bassetti, ... Intensive care medicine 46 (8), 1524-1535, 2020 | 351 | 2020 |
| Performance of Candida Real-time Polymerase Chain Reaction, β-D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis MH Nguyen, MC Wissel, RK Shields, MA Salomoni, B Hao, EG Press, ... Clinical infectious diseases 54 (9), 1240-1248, 2012 | 344 | 2012 |
| Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections PD Tamma, EL Heil, JA Justo, AJ Mathers, MJ Satlin, RA Bonomo Clinical Infectious Diseases, ciae403, 2024 | 343 | 2024 |
| Coronavirus disease 2019, superinfections, and antimicrobial development: what can we expect? CJ Clancy, MH Nguyen Clinical Infectious Diseases 71 (10), 2736-2743, 2020 | 339 | 2020 |
| Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant … PD Tamma, SL Aitken, RA Bonomo, AJ Mathers, D Van Duin, CJ Clancy Clinical Infectious Diseases 75 (2), 187-212, 2022 | 326 | 2022 |
| Diagnosing invasive candidiasis CJ Clancy, MH Nguyen Journal of clinical microbiology 56 (5), 10.1128/jcm. 01909-17, 2018 | 279 | 2018 |
| Do In Vitro Susceptibility Data Predict the Microbiologic Response to Amphotericin B? Results of a Prospective Study of Patients with Candida Fungemia MH Nguyen, CJ Clancy, VL Yu, YC Yu, AJ Morris, DR Snydman, ... Journal of Infectious Diseases 177 (2), 425-430, 1998 | 271 | 1998 |
| Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae … RK Shields, MH Nguyen, L Chen, EG Press, BN Kreiswirth, CJ Clancy Antimicrobial agents and chemotherapy 62 (5), 10.1128/aac. 02497-17, 2018 | 269 | 2018 |
| Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance G Haidar, NJ Philips, RK Shields, D Snyder, S Cheng, BA Potoski, Y Doi, ... Clinical Infectious Diseases 65 (1), 110-120, 2017 | 267 | 2017 |
